Ziopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial
ZIOPHARM Oncology Inc (ZIOP)
Last ziopharm oncology inc earnings: 3/2 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ziopharm.com
Company Research
Source: GlobeNewswire
BOSTON, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that it rapidly completed enrollment and treated a total of 36 patients in less than six months in a substudy (Clinicaltrials.gov NCT03679754) to expand a Phase 1 trial evaluating its Controlled IL-12 platform as a monotherapy for the treatment of recurrent glioblastoma (rGBM). The trial was over enrolled with eleven more patients than the target goal of 25, which the Company attributes to enthusiasm stemming from the trial’s encouraging survival and tumor biopsy data. Ziopharm is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as a drug to control the production of interleukin 12 (IL-12). In the setting for the treatment of rGBM, previously reported Phase 1 data demonstrated an increased survival benefit when using 20mg of veledimex, which is extended further when patients also received low-dose steroids versus higher doses. A majority of the newly enrolled pa
Show less
Read more
Impact Snapshot
Event Time:
ZIOP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZIOP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZIOP alerts
High impacting ZIOPHARM Oncology Inc news events
Weekly update
A roundup of the hottest topics